In a phase II study of 41 HCC patients who underwent surgical resection, adjuvant GPC3 vaccine administration significantly reduced the recurrence rate (1- and 2-year recurrence rates of 24% vs. 48% and 52.4% vs. 61.9%, respectively; P = 0.047, 0.387). Here, GPC3 is linked to hepatocellular carcinoma.